Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pneumonia IV: Management01:28

Pneumonia IV: Management

429
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
429
Acute Pharyngitis01:30

Acute Pharyngitis

1.3K
Introduction
Acute pharyngitis is the inflammation of the back of the throat (pharynx), commonly resulting in a sore throat. It is a frequently encountered condition that prompts individuals to seek medical advice.
Classification
Acute pharyngitis can be categorized based on its underlying cause:
1.3K
Angina IV: Management01:26

Angina IV: Management

16
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
16
Peritoneal Dialysis III: Nursing Management01:25

Peritoneal Dialysis III: Nursing Management

115
Peritoneal dialysis, or PD, utilizes the peritoneal membrane as a filter to eliminate excess fluid and waste products. Effective nursing management is essential for ensuring patient safety, preventing complications, and promoting optimal function of the peritoneal dialysis process.Assessment and MonitoringNurses must thoroughly assess the patient before, during, and after each dialysis session. Regular monitoring includes vital signs, daily weight, fluid intake and output, and laboratory values...
115
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

129
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
129
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

16
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
16

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparative Analysis Between the EuroClonality-NGS Approach and the LymphoTrack<sup>®</sup> Dx Assay for IG/TR Marker Screening in Lymphoid Leukemias: A Campus ALL Study.

International journal of molecular sciences·2026
Same author

Genetics and MRD for therapy allocation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia.

Blood·2026
Same author

Real-world effectiveness and safety of blinatumomab in adults with B-cell precursor acute lymphoblastic leukaemia across 13 European countries.

Blood cancer journal·2026
Same author

Optimal management of elderly/old Ph<sup>+</sup> acute lymphoblastic leukemia patients.

Haematologica·2026
Same author

Immunomodulatory effect of dasatinib plus blinatumomab versus ponatinib plus blinatumomab in newly diagnosed Ph+ acute lymphoblastic leukemia.

Leukemia·2026
Same author

Real-life management of 476 older adults with Philadelphianegative acute lymphoblastic leukemia: a Campus ALL study.

Haematologica·2026
Same journal

RETRACTED: Sabir et al. DNA Based and Stimuli-Responsive Smart Nanocarrier for Diagnosis and Treatment of Cancer: Applications and Challenges. <i>Cancers</i> 2021, <i>13</i>, 3396.

Cancers·2026
Same journal

Correction: Adeluola et al. Chemoprevention of 4-NQO-Induced Oral Cancer by the Combination of Resveratrol and EGCG: In Vivo, In Silico and In Vitro Studies. <i>Cancers</i> 2026, <i>18</i>, 1098.

Cancers·2026
Same journal

Correction: Peñalver et al. Guidelines for Diagnosis, Treatment, and Follow-Up of Patients with Follicular Lymphoma-Spanish Lymphoma Group (GELTAMO) 2026. <i>Cancers</i> 2026, <i>18</i>, 395.

Cancers·2026
Same journal

Correction: Accorsi Buttini et al. Development of a Simplified Geriatric Score-4 (SGS-4) to Predict Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation in Patients Aged over 50. <i>Cancers</i> 2025, <i>17</i>, 3278.

Cancers·2026
Same journal

Age-Stratified Long-Term Outcomes of Immune Checkpoint Inhibitors for Stage IV Melanoma and NSCLC in The Netherlands: A Population-Based Study.

Cancers·2026
Same journal

Targeting Ferroptosis in Glioblastoma: Molecular Mechanisms, Tumor Microenvironment, and Therapeutic Opportunities.

Cancers·2026
See all related articles

Related Experiment Video

Updated: Aug 25, 2025

Phage Phenomics: Physiological Approaches to Characterize Novel Viral Proteins
09:40

Phage Phenomics: Physiological Approaches to Characterize Novel Viral Proteins

Published on: June 11, 2015

12.3K

Modern Management Options for Ph+ ALL.

Josep-Maria Ribera1, Sabina Chiaretti2

  • 1Clinical Hematology Department, ICO-Hospital Germans Trias i Pujol, Josep Carreras Research Institute, Universitat Autònoma de Barcelona, 08916 Badalona, Barcelona, Spain.

Cancers
|October 14, 2022
PubMed
Summary
This summary is machine-generated.

Advances in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) management include less toxic chemotherapy and improved survival rates with tyrosine kinase inhibitors and immunotherapy. New therapies are enhancing treatment selection and outcomes for patients.

Keywords:
Philadelphia chromosomeacute lymphoblastic leukemiamodern management

More Related Videos

Using Phage Display to Develop Ubiquitin Variant Modulators for E3 Ligases
06:30

Using Phage Display to Develop Ubiquitin Variant Modulators for E3 Ligases

Published on: August 27, 2021

3.2K
Scalable High Throughput Selection From Phage-displayed Synthetic Antibody Libraries
12:55

Scalable High Throughput Selection From Phage-displayed Synthetic Antibody Libraries

Published on: January 17, 2015

18.7K

Related Experiment Videos

Last Updated: Aug 25, 2025

Phage Phenomics: Physiological Approaches to Characterize Novel Viral Proteins
09:40

Phage Phenomics: Physiological Approaches to Characterize Novel Viral Proteins

Published on: June 11, 2015

12.3K
Using Phage Display to Develop Ubiquitin Variant Modulators for E3 Ligases
06:30

Using Phage Display to Develop Ubiquitin Variant Modulators for E3 Ligases

Published on: August 27, 2021

3.2K
Scalable High Throughput Selection From Phage-displayed Synthetic Antibody Libraries
12:55

Scalable High Throughput Selection From Phage-displayed Synthetic Antibody Libraries

Published on: January 17, 2015

18.7K

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) management has evolved significantly.
  • Initial treatments combined imatinib with chemotherapy, leading to toxicity concerns.

Purpose of the Study:

  • To review and update the modern management strategies for Ph+ ALL.
  • To highlight recent advancements in treatment efficacy and patient outcomes.

Main Methods:

  • Review of concurrent imatinib and chemotherapy.
  • Analysis of attenuated chemotherapy regimens.
  • Evaluation of third-generation tyrosine kinase inhibitors (TKIs) and immunotherapy combinations.
  • Assessment of measurable residual disease (MRD) and ABL1 mutation detection.

Main Results:

  • Attenuated chemotherapy shows comparable efficacy with reduced toxicity.
  • Upfront third-generation TKIs improve molecular response and survival.
  • TKI and immunotherapy combinations achieve 70-80% molecular response, translating to 75-90% survival.
  • Allogeneic stem cell transplantation's role is being redefined.

Conclusions:

  • Modern Ph+ ALL management has dramatically improved outcomes.
  • Enhanced MRD and mutation detection aid treatment selection for newly diagnosed and R/R patients.
  • Emerging therapies, including cellular therapy, show promise for current and future first-line treatment.